Patients were centrally randomised in a 1:1 ratio to the control group ( 5-HT3-receptor antagonist + dexamethasone ) or aprepitant group ( 5-HT3-receptor antagonist + dexamethasone + aprepitant or fosaprepitant ) in the first course .